U.S. markets closed

Amarin Corporation plc (AMRN)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
5.40-0.04 (-0.74%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close5.44
Open5.39
Bid5.31 x 3200
Ask5.41 x 1000
Day's Range5.32 - 5.52
52 Week Range3.84 - 9.25
Volume2,763,392
Avg. Volume3,605,228
Market Cap2.135B
Beta (5Y Monthly)2.24
PE Ratio (TTM)540.00
EPS (TTM)0.01
Earnings DateNov 03, 2021 - Nov 08, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est10.75
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
-61% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Amarin Corporation plc
    EXEL: What does Argus have to say about EXEL?EXELIXIS INC has an Investment Rating of HOLD; a target price of $21.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    3 days agoArgus Research
View more
  • TheStreet.com

    Amarin Charts Are Charting a Course Toward Improvement

    However, traders will need to show a lot of patience if they buy shares of the biopharmaceutical company.

  • GlobeNewswire

    Amarin Outlines New Go-to-Market Strategy to Accelerate VASCEPA® (Icosapent Ethyl) Growth in U.S.

    Enables Amarin to Drive Additional Demand, Improve Patient Access & Education and Secure Proper Fulfillment and ReimbursementDUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN) today outlined its new Go-to-Market strategy to accelerate growth of VASCEPA® (icosapent ethyl) in the United States, which focuses on expanding healthcare professional engagement through a new omnichannel platform, enhancing managed care access and optimizing VA

  • GlobeNewswire

    Amarin Announces First European Launch of VAZKEPA (icosapent ethyl) in Germany

    Brings groundbreaking therapy to patients in Germany with residual cardiovascular risk and marks key milestone in corporate growth strategyDUBLIN, Ireland and BRIDGEWATER, N.J., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced the first European launch of VAZKEPA (icosapent ethyl) in Germany. VAZKEPA received marketing authorization from the European Commission in March 2021 and the Medicines and Healthcare Products Regulatory Agency (MHRA) in Great Britain